Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 108.40 | 242.27 | 162.78 | 468.07 |
Cash Equivalents | 60.61 | 0.08 | 0.07 | 0.68 |
Short Term Investments | 358.82 | 204.48 | 145.54 | 54.79 |
Cashand Short Term Investments | 527.82 | 446.83 | 308.39 | 523.54 |
Accounts Receivable- Trade Net | 1,863.04 | 1,659.73 | 1,313.41 | 1,476.50 |
Total Receivables Net | 2,047.90 | 1,856.79 | 1,495.64 | 1,608.39 |
Total Inventory | 1,589.10 | 1,459.34 | 1,559.27 | 1,552.48 |
Prepaid Expenses | 30.44 | 19.86 | 33.05 | 16.05 |
Other Current Assets Total | 64.65 | 53.10 | 27.75 | 17.00 |
Total Current Assets | 4,259.92 | 3,835.91 | 3,424.10 | 3,717.45 |
Property/ Plant/ Equipment Total- Gross | 3,704.79 | 3,319.44 | 2,917.04 | 2,843.48 |
Accumulated Depreciation Total | -1,307.58 | -1,104.69 | -931.58 | -910.33 |
Property/ Plant/ Equipment Total- Net | 2,397.21 | 2,214.76 | 1,985.46 | 1,933.15 |
Goodwill Net | 378.69 | 217.74 | 217.40 | 397.48 |
Intangibles Net | 507.77 | 125.81 | 161.36 | 383.22 |
Long Term Investments | 19.99 | 58.15 | 46.13 | 8.28 |
Note Receivable- Long Term | 104.53 | 83.41 | 85.23 | 217.27 |
Other Long Term Assets Total | 138.07 | 136.76 | 143.80 | 150.55 |
Total Assets | 7,806.16 | 6,672.53 | 6,063.47 | 6,807.40 |
Accounts Payable | 1,309.37 | 1,086.11 | 1,125.19 | 972.19 |
Accrued Expenses | 193.07 | 173.69 | 155.79 | 173.32 |
Notes Payable/ Short Term Debt | 961.98 | 1,145.33 | 1,090.96 | 1,252.67 |
Current Portof LT Debt/ Capital Leases | 390.66 | 329.66 | 297.68 | 385.96 |
Other Currentliabilities Total | 355.41 | 284.41 | 295.21 | 624.03 |
Total Current Liabilities | 3,210.47 | 3,019.19 | 2,964.83 | 3,408.18 |
Long Term Debt | 761.92 | 737.18 | 707.76 | 700.29 |
Capital Lease Obligations | 220.42 | 122.14 | 120.81 | 120.49 |
Total Long Term Debt | 982.34 | 859.32 | 828.56 | 820.78 |
Total Debt | 2,334.97 | 2,334.30 | 2,217.20 | 2,459.41 |
Deferred Income Tax | 137.42 | 38.90 | 42.61 | 39.88 |
Minority Interest | 169.48 | 148.53 | 126.59 | 94.99 |
Other Liabilities Total | 354.17 | 105.47 | 113.32 | 170.55 |
Total Liabilities | 4,853.88 | 4,171.41 | 4,075.92 | 4,534.38 |
Common Stock Total | 181.15 | 180.85 | 180.85 | 180.85 |
Additional Paid- In Capital | 9.88 | - | - | 84.04 |
Retained Earnings( Accumulated Deficit) | 2,712.52 | 2,293.77 | 1,791.03 | 1,932.12 |
Other Equity Total | 48.73 | 26.50 | 15.67 | 76.02 |
Total Equity | 2,952.28 | 2,501.13 | 1,987.55 | 2,273.02 |
Total Liabilities Shareholders' Equity | 7,806.16 | 6,672.53 | 6,063.47 | 6,807.40 |
Total Common Shares Outstanding | 18.91 | 18.91 | 18.91 | 18.91 |
Tangible Book Valueper Share Common Eq | 109.25 | 114.10 | 85.08 | 78.92 |
Emcure Pharmaceuticals Dividend Emcure Pharmaceuticals Bonus Emcure Pharmaceuticals News Emcure Pharmaceuticals AGM Emcure Pharmaceuticals Rights Emcure Pharmaceuticals Splits Emcure Pharmaceuticals Board Meetings Emcure Pharmaceuticals Key Metrics Emcure Pharmaceuticals Shareholdings Emcure Pharmaceuticals Profit Loss Emcure Pharmaceuticals Cashflow Emcure Pharmaceuticals Q1 Results Emcure Pharmaceuticals Q2 Results Emcure Pharmaceuticals Q3 Results Emcure Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks